pentobarbital raises toxicity of buprenorphine, lengthy-acting injection by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of buprenorphine and benzodiazepines or other CNS depressants improves hazard of adverse reactions including overdose, respiratory melancholy, and Demise. Cessation of benzodiazepines or other CNS depressants is desired normally.
Drugs which have stage therapy linked with Every single prescription. This restriction commonly necessitates that certain requirements be satisfied just before approval for your prescription.
pentobarbital will lessen the level or impact of vincristine liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Unidentified.
pentobarbital will decrease the extent or impact of phenytoin by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.
Occasionally, checking at a better degree of care for tapering CNS depressants may be correct. In Many others, progressively tapering a affected person off of the prescribed benzodiazepine or other CNS depressant or reducing to the lowest effective dose may very well be ideal.Serious - Use Alternative (1)buprenorphine, extended-acting injection and pentobarbital both of those maximize sedation. Stay clear of or Use Alternate Drug. Limit use to patients for whom substitute therapy solutions are inadequate
pentobarbital will increase toxicity of ifosfamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of. CYP3A4 inducers may enhance the metabolism of ifosfamide to its Lively alkylating get more info metabolites.
pentobarbital will minimize the extent or effect of sufentanil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Not known.
pentobarbital will decrease the level or outcome of methadone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
pentobarbital decreases amounts of ponatinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Stay clear of or Use Alternate Drug. Steer clear of Until the coadministration outweighs the probable danger of ponatinib underexposure; check for signs of diminished efficacy.
pentobarbital will lower the extent or influence of siponimod by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of siponimod with a drug that triggers average CYP2C9 in addition a moderate or sturdy CYP3A4 inducer isn't proposed.
pentobarbital will decrease the extent or effect of triazolam by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
pentobarbital will lessen the extent or result of osilodrostat by impacting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will reduce the level or impact of parecoxib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
pentobarbital will lower the level or outcome of eltrombopag by influencing hepatic enzyme CYP2C9/10 metabolism. Use Caution/Observe.